Fig. 3
From: A PSMA-targeted theranostic approach is unlikely to be efficient in serous ovarian cancers
Representative slides of pre-chemotherapy PSMA immuno-staining in a sensitive (a), a partially sensitive (b) and a resistant (c) serous epithelial ovarian cancer. A very partial immuno-staining of tumour neovascularization can be seen in panel b. Lower panels correspond to positive controls: refractory thyroid cancer (d) and normal prostate tissue (e). For refractory thyroid cancer (d), we observe an immuno-staining of neovascularization, while for prostate cancer (e) there is an immuno-staining of prostate glandular cells